Physician profile
Kimberly Pullen
NPI 1881923530
$5,574.71
in general payments reported to CMS, 2019-2025
31 companies · $164 in 2025
The $164 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,467 · 2022: $2,936 · 2023: $635 · 2024: $372 · 2025: $164.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,171.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,171.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $1,328.71 | 2022 | |
| Glaxosmithkline, LLC. | $679.18 | 2021-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $652.22 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $482.22 | 2021-2024 | Airsupra |
| Abbvie INC. | $346.39 | 2021-2024 | |
| Lilly USA, LLC | $281.69 | 2022-2024 | Zepbound, Emgality, Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $230.32 | 2021-2024 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $208.98 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $174.76 | 2021-2023 | Jardiance |
| Astellas Pharma US INC | $166.84 | 2021-2024 | Veozah |
| Abbott Laboratories | $147.74 | 2021-2025 | Freestyle Libre 3 |
| Idorsia Pharmaceuticals US INC | $122.65 | 2022 | |
| Pfizer INC. | $115.88 | 2021-2025 | |
| Exact Sciences Corporation | $82.17 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Biohaven Pharmaceuticals, INC. | $60.12 | 2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $58.74 | 2022-2023 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $49.23 | 2022-2024 | Capvaxive, Gardasil 9, Gardasil |
| Xeris Pharmaceuticals, INC. | $48.98 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $47.23 | 2022-2023 | Xarelto |
| Sanofi Pasteur INC. | $37.77 | 2023 | |
| Genentech USA, INC. | $37.00 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $33.43 | 2022 | |
| Amgen INC. | $27.61 | 2021 | |
| Scilex Pharmaceuticals INC. | $26.13 | 2022 | |
| Mylan Specialty L.P. | $24.51 | 2023 | Yupelri |
| Amarin Pharma, INC. | $19.66 | 2022 | |
| Corcept Therapeutics | $18.89 | 2025 | Korlym |
| Dynavax Technologies Corporation | $18.19 | 2024 | Heplisav-B |
| Otsuka America Pharmaceutical, INC. | $17.12 | 2022 | |
| Currax Pharmaceuticals LLC | $15.79 | 2025 | Contrave |
| Takeda Pharmaceuticals U.S.A., INC. | $14.56 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Pullen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.